Imbruvica, a blood cancer treatment, has made progress in discussing the expansion of insurance benefits about a year after passing the cancer disease review committee. According to the related industry, Imbruvica's first-line indication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) passed the HIRA drug reimbursement evaluation committee on the 3rd. Imbruvica's primary therapy indication was presented to the review committee three times from October 2021 to June 2022, but it did not pass. After that, it passed the review committee in September of last year and passed after being presented to the drug evaluation committee in August 2023.

In the meantime, there have been many